Sunday, January 21, 2018
Braeburn Receives Complete Response Letter for CAM2038 Injectable Buprenorphine Depot for the Treatment of Opioid Use Disorder
PRINCETON, N.J., Jan. 21, 2018 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the new drug application (NDA) for CAM2038, an investigational buprenorphine weekly and monthly depot injecti.....
Pharmacists Dr Sanjeev Hansraj Seenath Most influential Young Healthcare Professional In Jacksonville Florida
Helping, what does that mean when it comes to career choices? One young man with a passion for caring and a knack for the sciences decided to enter the workforce as a D...
NJHA Presents Annual 'Healthcare Leader' Awards
PRINCETON, Jan. 19, 2018 /PRNewswire-USNewswire/ -- The New Jersey Hospital Association, the state's oldest and largest healthcare trade association, today held its annual awards program to honor several individuals and organizations for their commitment to the state's healthcare system and the patients and communities they.....
BlueCare Anywhere Enhances Arizonans' Telehealth Options
PHOENIX, Jan. 19, 2018 /PRNewswire-USNewswire/ -- Expanding its telehealth services, Blue Cross Blue Shield of Arizona (BCBSAZ) announces the BlueCare Anywhere program to connect its customers with affordable and convenient services from their phones or mobile devices. BlueCare Anywhere.....
Kaiser Permanente Study Finds Cognitive Behavioral Therapy Is Cost-Effective for Teens Who Decline Antidepressants
PORTLAND, Ore., Jan. 19, 2018 /PRNewswire/ -- Cognitive behavioral therapy (or CBT) delivered in a primary care setting is a cost-effective way to treat adolescents with depression who decline or quickly stop using antidepressants, according to a Kaiser Permanente study published today in the journal Pediatrics.
Impact of the Zika Contraception Access Network (Z-CAN) for Women in Puerto Rico Highlighted in The Lancet Public Health
ATLANTA, Jan. 18, 2018 /PRNewswire-USNewswire/ -- In 2016 during the Zika virus outbreak, Puerto Rico had the highest number of Zika infections in the United States, a high rate of unintended pregnancy and limited access to contraception, including long-acting .....
Global CNS Therapeutics Industry
LONDON, Jan. 18, 2018 /PRNewswire/ --

Download the full report:

The report provides separate comprehensive analytics for the US, Cana.....
Sunrise House & C.L.E.A.R Announce Expansion of Program Helping People Recover from Addiction
LAFAYETTE, N.J., Jan. 18, 2018 /PRNewswire/ -- At a time when Sussex County is facing an opioid epidemic, Sunrise House Treatment Center and the Sussex County Community Law Enforcement Addiction Recovery (C.L.E.A.R.) Program a.....
Global Heparin Market is Expected to Reach US$ 14,853.1 Mn by 2025 - Credence Research
The latest market report published by Credence Research, Inc. “Heparin Market...

In Case You Missed It: Modern Living with kathy ireland® Features Hardy Nutritionals® to Spotlight How They’re Changing the Way We See Nutrition
(LOS ANGELES, January 18, 2018) -- Modern Living with kathy ireland® recently featured an exclusive story featuring David Hardy, Founder of  
MVC Eye Care Rebrands and Expands with New Windham, NH, Address

MANCHESTER, N.H. (PRWEB) January 18, 2018

Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist
NEW HAVEN, Conn., Jan. 18, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (Biohaven or the "Company") and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation.....
Morneau Shepell qualified as OTN Vendor of Record for Digital Mental Health Services
Ontario healthcare providers now able to access award-winning, multi-modality counselling program
Global Wound Debridement Products Market to Reach Worth US$ 493.1 Mn by 2025 - Credence Research
According to the latest report published by Credence Research, Inc. “ 
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
NEW YORK, Jan. 17, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it has acquired the global rights to develop and market dextromethadone (REL-1017), a novel N-methyl-D-aspartate.....


About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines